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Abstract
Bone metastasis remains a major cause of mortality and morbidity in breast cancer. Therefore, there is an urgent need to
better select high-risk patients in order to adapt patient’s treatment and prevent bone recurrence. Here, we found that integrin
alpha5 (ITGA5) was highly expressed in bone metastases, compared to lung, liver, or brain metastases. High ITGA5
expression in primary tumors correlated with the presence of disseminated tumor cells in bone marrow aspirates from early
stage breast cancer patients (n= 268; p= 0.039). ITGA5 was also predictive of poor bone metastasis-free survival in two
separate clinical data sets (n= 855, HR= 1.36, p= 0.018 and n= 427, HR= 1.62, p= 0.024). This prognostic value
remained significant in multivariate analysis (p= 0.028). Experimentally, ITGA5 silencing impaired tumor cell adhesion to
fibronectin, migration, and survival. ITGA5 silencing also reduced tumor cell colonization of the bone marrow and formation
of osteolytic lesions in vivo. Conversely, ITGA5 overexpression promoted bone metastasis. Pharmacological inhibition of
ITGA5 with humanized monoclonal antibody M200 (volociximab) recapitulated inhibitory effects of ITGA5 silencing on
tumor cell functions in vitro and tumor cell colonization of the bone marrow in vivo. M200 also markedly reduced tumor
outgrowth in experimental models of bone metastasis or tumorigenesis, and blunted cancer-associated bone destruction.
ITGA5 was not only expressed by tumor cells but also osteoclasts. In this respect, M200 decreased human osteoclast-
mediated bone resorption in vitro. Overall, this study identifies ITGA5 as a mediator of breast-to-bone metastasis and raises
the possibility that volociximab/M200 could be repurposed for the treatment of ITGA5-positive breast cancer patients with
bone metastases.
Introduction
Breast cancer can be successfully treated when the disease
is detected early, but the patient survival markedly decrea-
ses once metastatic spread occurs [1]. In this respect, the
prognosis for patients with bone metastasis is generally poor
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and accompanied by skeletal complications (pathological
fractures, bone pain, disability) [2]. Several studies have
underlined that tumor cell dissemination to the bone marrow
is an early metastasis event and represents an independent
prognostic factor for poor clinical outcome [3–5]. The bone
marrow acts as a reservoir where disseminated tumor cells
(DTCs) could survive in a cell-cycle arrest state for long
periods of time until environmental conditions are suffi-
ciently permissive for proliferation, at which time they
become competent to seed secondary organs and/or cause
overt local bone metastasis [6–8]. Molecular mechanisms
regulating bone homing and colonization by breast cancer
cells remain, however, still poorly understood.
In this study, we searched for potential target genes
involved in breast cancer dissemination to distant organs
using in silico transcriptomic analyses of primary tumors
and metastases. We found that integrin alpha5 (ITGA5) is
expressed at high levels in bone metastases compared to
non-bone metastases. Furthermore, multivariate analysis
showed that ITGA5 expression in primary breast tumors is
an independent prognostic factor for bone relapse. ITGA5
heterodimerizes with integrin beta1 to form the fibronectin
receptor α5β1 [9]. In breast cancer, ITGA5 mediates tumor
cell adhesion, extracellular matrix-guided directional
migration along fibronectin, and tumor cell survival in vitro
[9–13]. ITGA5 also mediates lung metastasis in animal
models of breast cancer [14, 15]. Additionally, a synthetic
peptide inhibitor derived from the synergy region of fibro-
nectin that binds to α5β1 and αvβ3 integrins (ATN-161,
also called PHSCN) reduces both MDA-MB-231 breast
cancer bone metastasis formation and skeletal tumor out-
growth [14, 16]. However, ATN-161 interacts with αvβ3
[16], and the treatment of tumor-bearing animals with a
specific nonpeptide antagonist of αvβ3 (PSK 1404) also
inhibits bone metastasis formation [17], suggesting that the
inhibitory effect of ATN-161 on bone metastasis formation
was mediated through the therapeutic targeting of αvβ3.
Besides ATN-161, a humanized IgG4 monoclonal antibody
against α5β1, known as M200 (volociximab), was devel-
oped as an antiangiogenic agent for the treatment of solid
tumors and age-related macular degeneration [18, 19]. A
phase I study conducted in 22 patients with advanced stage
solid tumors showed that the pharmaco-toxicologic profile
of M200 is safe, and preliminary evidence of antitumor
activity was reported in one patient with renal cell carci-
noma [18]. Clinical trials also evaluated its safety in the
treatment of ovarian cancer and non-small cell lung cancer,
as a single agent or in combination with chemotherapy
[20, 21].
Here, we provide evidence that ITGA5 is a mediator of
bone metastasis and a potential therapeutic target for bone
metastasis treatment. Using genetic overexpression or
silencing strategies, we show that ITGA5 in breast cancer
cells mediates metastatic tumor cell colonization of the bone
marrow and promotes formation of osteolytic lesions
in vivo. Furthermore, we show that M200 could be effective
in the treatment of breast cancer patients with osteolytic
bone metastases by targeting both tumor cells and osteo-
clasts, the latter being bone-resorbing cells that mediate
cancer-induced bone destruction.
Results
ITGA5 is a bone metastasis-associated gene in
breast cancer
We compared the transcriptomic profile of 21 bone metas-
tases with that of 59 metastases from other distant organs.
This analysis identified 246 genes (gene set #1) that were
expressed at higher levels in bone metastases compared to
non-bone metastases (Fig. 1A and Table S1). In parallel, the
analysis of 855 radically resected primary breast tumors with
known location of the first distant metastasis led to 146 genes
(gene set #2) that were significantly upregulated in primary
tumors from patients who first relapsed in bone, compared to
patients who first relapsed at non-bone metastatic sites or did
not relapse after 200 months follow-up (Fig. 1B and Table
S1). Eight genes were common to gene sets #1 and #2: EGF-
containing fibulin-like extracellular matrix protein 2
(EFEMP2), ITGA5, KIAA1199 (cell migration-inducing and
hyaluronan-binding protein), microfibrillar-associated protein
5 (MFAP5), plexin domain-containing protein 1 (PLXDC1),
SPARC (Osteonectin), Cwcv and kazal-like domains pro-
teoglycan 1 (SPOCK1), T-cell immune regulator 1 (TCIRG1),
and transforming growth factor beta1-induced transcript 1
(TGFB1I1) (Fig. 1C). Besides the role played by ITGA5 in
promoting breast cancer cell adhesion, invasion, and survival
[9–16], EFEMP2, KIAA1199, and MFAP5 also enhance
breast cancer motility and invasiveness [22–24]. SPOCK1
and TGFB1I1 (also called hydrogen peroxide-inducible clone
5) are induced by TGF-β and promote breast cancer cell
invasion [25, 26]. PLXDC1 increases invasion in gastric
cancer [27], and TCIRG1 is an osteoclast-specific vacuolar
proton pump subunit that acts as a metastasis enhancer in
hepatocellular carcinoma [27]. In addition, MFAP5 is upre-
gulated in human breast cancer bone metastases compared to
primary tumors [24].
The functional importance of these genes was assessed by
gene network analysis, revealing a prominent role for ITGA5,
given its high connectivity degree within the network structure
(Fig. S1). Moreover, as shown in Fig. 1D, ITGA5 was highly
expressed in bone metastases compared to lung (p= 0.001),
liver (p= 5.10−5), and brain (p= 3.10−4) metastases. We
therefore focused our attention to the role of ITGA5 in breast
cancer bone metastasis.
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ITGA5 is an independent prognostic factor for
breast cancer bone metastasis
We quantified ITGA5 expression levels in 427 radically
resected primary breast tumors [28]. Kaplan–Meier survival
analysis revealed that the risk of bone metastasis was sig-
nificantly higher for patients with high ITGA5 levels (HR=
1.62, p= 0.024) (Fig. 1E). Furthermore, ITGA5 predicted bone
relapse (p= 0.028) independently of clinicopathological char-
acteristics (Table 1). To confirm these findings, we conducted
in silico analysis of a cohort of 855 radically resected primary
mammary tumors with clinical annotation for recurrences and
observed that breast cancer patients with tumors expressing
high ITGA5 mRNA levels were more likely to relapse in bone
(HR= 1.36, p= 0.018) (Fig. S2). After adjusting for clin-
icopathological factors, ITGA5 remained significantly asso-
ciated with bone relapse (p= 0.034) (Fig. S2).
Elevated ITGA5 protein levels in primary tumors are
associated with the presence of DTCs in bone
marrow aspirates from patients with breast cancer
To examine the potential contribution of ITGA5 in the homing
of breast cancer cells to bone, we analyzed by immunohis-
tochemistry ITGA5 protein levels in 268 radically resected
primary tumors from a cohort of breast cancer patients with no
clinical signs of metastasis for whom the presence or absence
of DTCs in the bone marrow was documented (Table S2) [29].
A significantly higher percentage of breast cancer patients
having elevated ITGA5 protein levels in primary tumors were
DTC-positive (p= 0.039), compared to that observed for
patients with low ITGA5 levels in primary tumors (Fig. 1F and
Table S2). Additionally, flow cytometry analysis of a breast
cancer DTC cell line (BC-M1) [30, 31] showed cell surface
expression of integrin α5β1 (Fig. S3A).
Fig. 1 ITGA5 is a bone metastasis-associated gene in breast can-
cer. A Heat map analysis of genes that are highly expressed in bone
metastases (n= 21) compared to visceral metastases (n= 59). Each
row represents a gene, and each column represents a metastasis spe-
cimen. Class comparison analysis was performed using a univariate t-
test (p < 10−4, fold-change > 1.5). B Heat map of genes associated with
bone metastasis-free survival. Transcriptomic gene profile of 855
radically resected primary breast tumors was hierarchized according to
the location of the first distant metastasis. Bone metastasis-negative
patients: patients who first relapsed at non-bone sites or did not relapse
after 200 months follow-up. Bone metastasis-positive patients: patients
who first relapsed in bone after 100 months follow-up. C Venn dia-
gram of (a) genes upregulated in bone vs. visceral breast cancer
metastasis (gene set #1) and (b) genes upregulated in primary tumors
from patients with early occurrence of bone metastasis (gene set #2),
which underscores a set of eight genes (gene set #3) shared between
gene sets #1 and #2: EFEMP2 EGF-containing fibulin-like extra-
cellular matrix protein 2, ITGA5 integrin alpha5, KIAA1199 cell
migration-inducing and hyaluronan-binding protein (CEMIP), MFAP5
microfibrillar-associated protein 5, PLXDC1 plexin domain-containing
protein 1, SPOCK1 SPARC (osteonectin), Cwcv and kazal-like
domains proteoglycan 1, TCIRG1 T-cell immune regulator 1,
TGFB1l1 transforming growth factor beta1-induced transcript 1.
D ITGA5 mRNA expression levels in breast cancer metastases. Data
are expressed as mean ± SEM. E Kaplan–Meier estimates for rates of
bone metastasis-free survival of breast cancer patients (n= 427),
according to high and low ITGA5 expression levels. HR hazard ratio,
CI confident interval. HR and 95% CI are based on Cox univariate
analysis. F Percentage of breast cancer patients with DTCs in the bone
marrow according to high or low ITGA5 expression levels in matched
primary mammary tumors (n= 268). ITGA5+ ITGA5-high, ITGA5−
ITGA5-low. *p= 0.039.
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ITGA5 promotes breast cancer cell dissemination to
the bone marrow and formation of osteolytic bone
metastases in vivo
Human MDA-MB-231, Hs578T, and MDA-B02 breast
cancer cells, which are ER- and PR-negative and do not
bear an amplification of HER2 gene (referred to as triple-
negative breast cancer cells), had higher cell surface
expression levels of integrin α5β1 and higher ITGA5 pro-
tein levels than luminal A (T47D, MCF-7, BT-474) and
HER2-expressing luminal B (SKBr3) breast cancer cell
lines, as judged by flow cytometry and western blotting,
respectively (Fig. S3A, B). ITGA5 mRNA expression levels
in tumor cells were further investigated using 51 distinct
breast cancer cell lines with different molecular phenotypes
and degree of invasiveness (GSE12777) [32]. A significant
correlation was observed between high ITGA5 mRNA
expression levels and high tumor cell invasiveness (p=
0.0083) (Fig. S3C, D). In particular, the highest ITGA5
mRNA levels were observed in claudin-low, triple-negative
breast cancer cell lines (p < 0.01) (Fig. S3E).
We therefore silenced ITGA5 in claudin-low MDA-MB-
231 and MDA-B02 breast cancer cells, the latter being a
bone metastatic cell subpopulation of the MDA-MB-231
cell line, which constitutively and specifically overexpresses
αvβ3 integrin compared to the parental cell line [17, 33].
ShRNA-mediated silencing of ITGA5 in these cells drasti-
cally reduced ITGA5 expression, both at the protein and cell
surface expression levels compared to shRNA control cells
(Fig. 2A, B). The flow cytometry analysis of shITGA5-
MDA-MB-231 and shITGA5-MDA-B02 cells showed that
the silencing of ITGA5 did not modify cell surface
expression levels of integrin subunits α2, α3, α4, and β1 and
of αvβ3 integrin, when compared to shRNA control cells
(Figs. S4 and S5). The silencing of ITGA5 led to a 60%
reduction of tumor cell adhesion to fibronectin (Fig. S6A),
whereas tumor cell adhesion to glass, poly-D-Lysine, and
laminin remained unchanged (Fig. S6B). In addition, ITGA5
silencing reduced by half the number and size of mammo-
spheres formed by MDA-B02-shITGA5 cells, compared to
that observed with MDA-B02-shCtrl cells (Fig. S6C).
To investigate whether ITGA5 could drive tumor cell
anchorage in bone marrow in vivo, MDA-MB-231 cells that
have the propensity to form lung and bone metastases were
injected into the tail artery of immunodeficient mice and,
2 weeks after tumor cell inoculation, these animals were
culled and the number of micrometastases in bone marrow
and lungs quantified. Abrogating ITGA5 expression in
MDA-MB-231-ShITGA5 cells significantly reduced bone
marrow micrometastasis formation (p= 0.015), whereas the
extent of tumor cell dissemination to lungs remained
unchanged, compared to MDA-MB-231-Sh-Ctrl cells
(Fig. 2C). These results may be explained by the fact that
fibronectin was strongly expressed in bone tissue, whereas
only a weak expression was observed in lungs, the immu-
nostaining being essentially localized around blood vessels
within the lung parenchyma (Fig. 2D). Moreover, high
fibronectin expression levels in bone marrow stroma were
observed compared to lung parenchyma, when analyzing
EST profiles of Mus Musculus and Homo Sapiens tissue
samples (Fig. S7). Thus, these data suggested that ITGA5
preferentially mediates tumor cell anchorage in the bone
marrow by binding to fibronectin.
To determine whether ITGA5 could play a role in the
formation and progression of bone metastases, bone-seeking
MDA-B02 cells, silenced or not silenced for ITGA5, were
injected into the tail artery of immunodeficient mice.
Radiographic analysis of tumor-bearing animals 4 weeks
after tumor cell inoculation showed a significant decrease
(p= 0.0268) of the extent of osteolytic lesions in hind limbs
of mice injected with MDA-B02-shITGA5 cells compared
to that observed with MDA-B02-shCtrl cells (Fig. S8).
Experiments were also conducted with human MCF-7
breast cancer cells that express low amounts of ITGA5 (Fig.
S3A, B). Transduction of luciferase2-expressing MCF-7
cells (MCF-7-luc2) with a retroviral plasmid containing the
ITGA5 open reading frame (MCF-7-luc2-ITGA5) resulted
in a strong expression of integrin α5β1 (Fig. 3A, B). As
judged by flow cytometry analysis, ITGA5 overexpression
led to decreased cell surface expression levels of α2 and α3
integrins, whereas cell surface expression levels of α4, β1,
and αvβ3 remained unchanged, when compared to control
MCF-7-luc2 cells (Figs. S4 and S5). Integrins α2β1 and
α3β1 are acting as cell surface receptors for collagen
and laminin, respectively [34]. We cannot exclude a
decreased attachment of MCF-7-luc2-ITGA5 cells to
these extracellular matrix proteins. However, as expected,
Table 1 Association of ITGA5 expression with clinical and biological
characteristics of patients with early stage breast cancer from the Curie
Institute/Centre René Huguenin cohorta.





Age 1.000 0.985 1.016 0.965
Tumor size 1.003 0.991 1.015 0.650
Nodal status 2.635 1.271 5.462 0.009
Estrogen
receptor status
0.825 0.524 1.297 0.404
Progesterone
receptor status
1.267 0.858 1.872 0.234
Her2 status 0.784 0.526 1.170 0.234
ITGA5
expression
1.359 1.083 1.707 0.028
aHazard ratios and 95% confidence intervals (CIs) are based on Cox
multivariate regression analysis.
Bold value highlight statistically significant characteristics.
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MCF-7-luc2-ITGA5 cell adhesion and spreading to fibro-
nectin were increased compared to that observed with MCF-
7-luc2-Ctrl cells (Fig. 3C). MCF-7-luc2-ITGA5 or MCF-7-
luc2-Ctrl cells were therefore inoculated intra-arterially to
nude mice (Fig. 3D, E). Bioluminescence imaging revealed
an earlier onset (p= 0.0186) of skeletal tumor burden in
mice injected with MCF-7-luc2-ITGA5 cells, compared to
animals bearing MCF-7-luc2-Ctrl cells (Fig. 3D). Micro-
computed tomography of metastatic long bones showed that
the BV/TV ratio (a measure of the bone volume) was
decreased (p= 0.035) in mice inoculated with MCF-luc2-
ITGA5 cells, indicating a higher extent of bone destruction
compared to animals bearing MCF-7-luc2-Ctrl tumor cells
(Fig. 3E).
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Overall, these data indicated that ITGA5 mediates the
homing of breast cancer cells in the bone marrow and
promotes formation of osteolytic bone metastases in vivo.
Pharmacological inhibition of ITGA5 reduces breast
cancer cell dissemination to the bone marrow and
formation of osteolytic bone metastases in vivo
We examined the therapeutic potential of targeting ITGA5
for the treatment of bone metastasis, using a humanized
monoclonal antibody against α5β1 (M200, volociximab)
[18]. Antibody M200 selectively binds to human α5β1,
but not murine α5β1 [18]. In vitro, M200 treatment dose-
dependently decreased MDA-B02 cell adhesion to fibro-
nectin (p < 0.0003), but not to type I collagen, or vitro-
nectin (Fig. 4A). The paxillin immunofluorescent labeling
of focal adhesion contacts showed that M200 specifically
inhibited MDA-B02 and MDA-MB-231 cell spreading to
a fibronectin matrix, but not to type I collagen or vitro-
nectin (Fig. 4B). In line with this inhibitory effect on
tumor cell spreading, M200 treatment dose-dependently
reduced MDA-B02 cell migration through inserts coated
with fibronectin (p < 0.001) (Fig. 4C). In vivo, immuno-
deficient mice were treated with M200 or a negative
control IgG antibody beginning 1 day (D1) before intra-
arterial inoculation of MDA-B02 cells (D0). The treat-
ment with the antibody then continued every other day
until day 7, at which time animals were culled, and the
bone marrow collected and placed under antibiotic
selection, enabling the selective outgrowth of antibiotic-
resistant tumor cells (Fig. 4D). After 2 weeks in culture,
the average number of tumor cell colonies recovered in
the bone marrow from animals treated with M200 was
significantly impaired, compared to that recovered from
animals treated with a control IgG (7 ± 2 and 128 ± 10
colonies/well, respectively; p < 0.0003) (Fig. 4D). Using a
similar treatment protocol from D1 to D28 (Fig. 5A),
antibody M200 also significantly delayed the onset of
skeletal tumor burden and extent of osteolytic lesions in
animals (Fig. 5B, C). Histomorphometric analysis of
metastatic legs from M200-treated animals showed that
the BV/TV ratio was enhanced when compared with
control IgG-treated tumor-bearing animals (Fig. 5D). This
difference was accompanied by a sharp reduction in the
TB/STV ratio (a measure of the skeletal tumor burden)
(Fig. 5D). Moreover, immunostaining of metastatic legs
showed a concomitant decrease of Ki67 index, a measure
of tumor cell proliferation (M200, 15.5 ± 2.5% vs. Ctrl
IgG, 28.5 ± 2.5%; p < 0.05) (Fig. 5D).
To be free from the impact of bone-derived growth
factors released from resorbed bone that stimulate tumor
growth, the antitumor potential of antibody M200 was
investigated in animals bearing subcutaneous MDA-B02
tumor xenografts (Fig. 6A). A statistically significant
reduction of tumor growth was observed in M200-treated
tumor-bearing animals, compared to control IgG-treated
tumor-bearing animals (p < 0.005) (Fig. 6B, C). At day 35
after tumor cell inoculation, the median weight of tumors
from M200-treated animals was almost threefold lower than
that of tumors from Ctrl IgG-treated animals (p= 0.05)
(Fig. 6D). Similarly, ITGA5 silencing in MDA-B02 cells
substantially reduced subcutaneous growth of MDA-B02-
shITGA5 tumors compared to control (Fig. S9). Further-
more, cell-cycle analysis showed that M200 treatment
inhibited MDA-B02 cells entering into S phase, when
compared to that observed with a negative control IgG
antibody (Fig. S10). Thus, M200 exhibits a direct antitumor
effect in vitro and in vivo.
Anti-ITGA5 function-blocking antibody M200
decreases human osteoclast differentiation and
activity
M200 did not interfere with murine osteoclastogenesis
induced by RANKL and MCS-F in combination with the
conditioned medium from MDA-B02 cells (Fig. S11A), nor
did it modulate gene expression of murine osteoblast during
osteoblastogenesis in vitro (Fig. S11B). However, ITGA5 is
expressed in human osteoclasts [35]. We therefore tested
the effect of M200 on human osteoclasts, using PBMCs
treated with RANKL and MCS-F to induce osteoclast dif-
ferentiation, as previously described [36]. When compared
to cathepsin K (an osteoclast marker), osteoclasts did
express ITGA5, both at the mRNA and protein levels
(Fig. 7A, B). ITGA5 expression gradually decreased during
Fig. 2 ITGA5 in triple-negative MDA-MB-231 and MDA-B02
breast cancer cells promotes the burden of micrometastatic disease
in the bone marrow in vivo. A ITGA5 expression in MDA-MB-231
and MDA-B02 cells silenced for ITGA5 (shITGA5), compared to
control cell lines (shCtrl), as measured by western blotting. B Cell
surface expression levels of integrin α5β1 in MDA-MB-231 (left-hand
panel) and MDA-B02-shCtrl and shITGA5 cells (right-hand panel), as
measured by flow cytometry using anti-ITGA5 monoclonal antibody
IIA1 (red and black histograms) or an isotype-matched negative
control antibody (gray histograms). C Top-left panel: schematic
representation of the experimental protocol. MDA-MB-231-shCtrl or
MDA-MB-231-shITGA5 cells were inoculated intra-arterially to Balb/
c nude mice (n= 5 per group). Two weeks after tumor cell inoculation,
animals were culled, and the bone marrow and lungs collected for
tumor cell colony assays. Bottom-left panel: representative images of
tumor cell colonies in the bone marrow and lung are shown for each
cell line. Right panel: bar graphs showing the average number of
tumor cell colonies formed in the bone marrow and lungs for each cell
line. Data are expressed as the mean ± SEM. D Fibronectin immu-
nostaining in bone and lung. Right-hand panels are a magnification of
insets shown in left-hand panels. In bone, a strong immunostaining for
fibronectin was observed in osteoblasts (white arrows), osteocytes (red
asterisks), and endothelial cells (black arrows). In lungs, the immu-
nostaining was mainly localized around blood vessels.
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the course of osteoclast differentiation (Fig. 7B, C).
Nevertheless, M200 was nearly as potent as anti-RANKL
antibody denosumab to inhibit human osteoclast differ-
entiation in vitro, compared to a control IgG (Fig. 7D).
Furthermore, antibody M200 inhibited osteoclast activity,
decreasing by 80% the resorption of a synthetic inorganic
bone matrix (Fig. 7E). By contrast, it did not affect osteo-
clast viability (Fig. 7F).
Discussion
Our study establishes a bone metastasis-promoting role for
ITGA5 in breast cancer. Specifically, we report that high
ITGA5 levels in primary tumors were predictive of poor
bone metastasis-free survival in two separate clinical data
sets (HR= 1.36, p= 0.018 and HR= 1.62, p= 0.024).
Additionally, using a clinical cohort of breast cancer patients
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without any clinical signs of metastasis, we showed that high
ITGA5 expression levels in primary tumors correlated with
the presence of DTCs in the bone marrow. Moreover,
ITGA5 was expressed in human DTCs (this study and 12).
Our clinical data are consistent with those obtained in pre-
vious prospective clinical trials demonstrating that the risk of
recurrence in early stage breast cancer is significantly higher
in patients with detectable DTCs in the bone marrow than in
those without [3–5]. These findings ([3–5], [12], and this
study) collectively suggest that ITGA5 mediates DTC
colonization of the bone marrow. This contention was also
supported by our preclinical data. Using genetic silencing
and overexpression strategies or pharmacological inhibition,
we uncovered a specific association between ITGA5
expression levels in breast cancer and the development of
bone metastasis. Although bone is a predominant site of
metastasis for ER-positive breast cancer with a frequency as
high as 65–70%, triple-negative breast cancer exhibits a rate
of bone metastasis (39%) similar to lung metastasis (43%),
which is comparatively higher than that observed in other
distant metastatic sites such as brain (25%) and liver (21%)
[37]. ITGA5 could therefore contribute to the tropism of
triple-negative breast cancer cells to bone. Several factors
have been shown to regulate ITGA5 expression in triple-
negative breast cancer [10, 38–40]. For example, steroid
receptor coactivator (SRC-1), which is an ER transcriptional
coactivator, enhances ITGA5 expression in ER-negative
breast cancer cells [10]. Additional factors expressed by
human breast cancer cells, such as PTH-rP and angiopoietin-
2, promote tumor cell adhesiveness to fibronectin and tumor
cell motility and invasion through the specific upregulation
of ITGA5 [38, 39]. Conversely, members of the miR-30
family impede breast cancer bone metastasis formation by
directly targeting ITGA5 [40]. In this respect, ITGA5 silen-
cing in Hs578T cells (a triple-negative breast cancer cell line
expressing high ITGA5 levels) recapitulates inhibitory
effects of miR-30s on bone metastasis formation in vivo
[40]. Here, we found that abrogating ITGA5 in human
MDA-MB-231 cells also blunted tumor burden in the bone
marrow, whereas the formation of pulmonary micro-
metastases remained unaffected. These results may be
explained by the fact that fibronectin is naturally expressed
in the bone stroma, whereas its expression in lung par-
enchyma is essentially localized around blood vessels ([11],
[41], and this study). This observation does not preclude a
role for ITGA5 in lung metastasis. Indeed, ITGA5 has been
associated with lung metastasis in animal models of breast
cancer [14, 15]. However, our study suggests that additional
molecular mechanisms associated with lung metastasis for-
mation may likely compensate for the lack of ITGA5 in
human breast cancer cells, whereas ITGA5 is crucial for the
homing of these cancer cells in the bone marrow. It has
previously been reported that ITGA5 promotes survival of
breast cancer cells in the bone marrow [12]. Here, we
showed that ITGA5 silencing reduced the survival of breast
cancer cells (Fig. S6C). We therefore propose that ITGA5
provides breast cancer cells (and DTCs) with a survival
advantage by binding to fibronectin in the bone marrow,
which explains, at least in part, why high ITGA5 expression
levels in primary tumors predict the occurrence of future
bone metastases in patients with early stage breast cancer.
We previously reported that bone-seeking MDA-B02
cells specifically overexpress αvβ3 integrin, compared to
parental MDA-MB-231 cells ([33] and Fig. S5), and its
overexpression by MDA-MB-231 cells reproduces the bone
metastatic phenotype of MDA-B02 cells in vivo [17]. Here,
ITGA5 had a bone metastasis-promoting role, whereas
ITGA5 expression in MDA-B02 cells was 20% lower than
that observed in MDA-MB-231 cells (Fig. S4). Although
counterintuitive, expression levels of integrins are not
always a direct readout of integrin functions in cells [34].
Additional levels of regulation exist. Upon binding of
integrins to extracellular matrix proteins, there is a crosstalk
between integrins that determines downstream signaling and
cell behavior [34]. For example, α5β1 and αvβ3 integrins
both bind fibronectin and this is the collaborative interac-
tions among these two integrins rather than their respective
expression levels that determine cell migration response
toward fibronectin [42]. Interestingly, the knockdown of
integrin β1 in murine 4T1 triple-negative breast cancer cells
induces a compensatory increase in β3 integrin expression
and a switch in the migratory behavior of 4T1 cells from
collective to single cell movement in vitro that leads to
metastasis in vivo [43]. The β1 integrin subunit
Fig. 3 Overexpression of ITGA5 in human luminal A MCF-7
breast cancer cells promotes tumor cell adhesion to fibronectin
in vitro and enhances skeletal tumor burden and the extent of
metastatic osteolytic lesions in vivo. A Western blot analysis of
ITGA5 in MCF-7-luc2 cells (MCF-7 Ctrl) after transduction with the
retroviral plasmid (MCF-7 ITGA5). B Flow cytometry analysis of cell
surface expression of α5β1 integrin in MCF-7-Ctrl and MCF-7-ITGA5
cells. C Left panels: representative images of MCF-7-Ctrl and MCF-7-
ITGA5 cell adhesion to fibronectin as a function of time. Right panel:
quantification of the number of adherent cells to fibronectin at 20 and
40 min. *p < 0.001; **p < 0.0001. D Top panel: schematic repre-
sentation of the experimental protocol. MCF-7-luc2-Ctrl or MCF-7-
luc2-ITGA5 cells were inoculated intra-arterially to Balb/c nude mice
(n= 4–5 per group). Eighty days after tumor cell inoculation, animals
were analyzed by bioluminescence imaging, and histomorphometry of
metastatic legs was measured by microcomputed tomography (μCT).
Bottom-left panel: whole-body bioluminescence imaging of a repre-
sentative animal for each group at day 80 after tumor cell inoculation.
Bottom-right panel: Kaplan–Meier estimates for rates of invasive-
disease-free survival (IDFS) of animals, as measured by biolumines-
cence imaging. E Left panel: μCT of representative metastatic tibiae
for each group. Right panel: Assessment of bone destruction by his-
tomorphometry, as measured by the bone volume (BV)/tissue volume
(TV) ratio of metastatic legs from mice injected with MCF-7-luc2-Ctrl
(n= 5) or MCF-7-luc2-ITGA5 cells (n= 4).
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Fig. 4 Function-blocking humanized anti-ITGA5 monoclonal
antibody M200 specifically inhibits breast cancer cell adhesion and
spreading to fibronectin and blocks MDA-B02 cell colonization in
the bone marrow. A MDA-B02 cells treated or not treated with
increasing concentrations of M200 (50, 150, and 250 μg/ml) were
allowed to adhere for 1 h to human fibronectin, type I collagen, or
vitronectin. Attached cells were then fixed, stained, and counted under
microscope. Data are expressed as mean ± SEM of three separate
experiments. ***p < 0.0001. B Representative images of paxillin
immunofluorescent labeling of focal adhesion contacts (black spots at
the edge of the plasma membrane) in MDA-MB-231 and MDA-B02
cells treated with a control IgG or M200 (250 μg/ml) that attached and
spread to fibronectin, type I collagen, or vitronectin. C Effect of
increasing concentrations of control IgG or M200 (50, 150, and
250 μg/ml) on MDA-B02 cell migration through 8-µm diameter pore-
size inserts coated with fibronectin. Data are the mean ± SEM of three
separate experiments. **p < 0.001; ***p < 0.0001. D Top-left panel:
schematic representation of the treatment protocol. MDA-B02 cells
were inoculated intra-arterially to Balb/c nude mice. Animals received
a treatment with a control IgG or M200 (15 mg/kg) every other day,
starting 1 day before tumor cell inoculation. Seven days after tumor
cell inoculation, animals were culled, and the bone marrow collected
for tumor cell colony assays. Bottom panel: representative images of
tumor cell colonies in the bone marrow from animals treated with
M200 or the control IgG.
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Fig. 5 Pharmacological inhibition of ITGA5 with M200 treatment
reduces bone metastasis formation in vivo. A Top panel: schematic
representation of the treatment protocol. MDA-B02 cells were
inoculated intra-arterially to Balb/c nude mice. Animals (ten mice per
group) received a treatment with a control IgG or M200 (15 mg/kg)
every other day, starting 1 day before tumor cell inoculation. Bone
metastasis formation in animals was monitored over time by biolu-
minescence imaging and radiography. Twenty-eight days after tumor
cell inoculation, animals were culled, and metastatic bones were
analyzed by histomorphometry and immunohistochemistry. B Left
panels: whole-body bioluminescence imaging of a representative
animal for each group at day 28. Middle panel: progression of tumor
burden in control IgG- and M200-treated animals, as measured by
whole-body bioluminescence imaging. Right panel: Kaplan–Meier
estimates for rates of invasive-disease-free survival (IDFS) of animals,
as measured by bioluminescence imaging. C Left panels: radiograph
of a representative metastatic leg for each group at day 28. Middle
panel: progression of osteolytic lesion areas in control IgG- and M200-
treated animals, as measured by radiography. Right panel:
Kaplan–Meier estimates for rates of bone metastasis-free survival
(BMFS) of animals, as measured by radiography. D Left panels:
Goldner’s trichrome staining of tibial tissue sections of metastatic legs
from tumor-bearing mice treated with the control IgG or M200. Bone
is stained green, whereas bone marrow (BM) and tumor cells are
stained purple. Middle panel: assessment of bone destruction and
tumor burden as measured, respectively, by the bone volume (BV)/
tissue volume (TV) ratio and tumor burden (TB)/soft tissue volume
(STV) ratio of metastatic legs from tumor-bearing mice treated with
the control IgG or M200. *P < 0.05. Right panel: representative
Ki67 staining of tumor areas in bone tissue sections from metastatic
legs of animals treated with the control IgG or M200.
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heterodimerizes with different α subunits [34], which prob-
ably explains why ITGA5 silencing did not modify cell
surface expression levels of β1 and αvβ3 in MDA-MB-231
and MDA-B02 cells (Figs. S4 and S5). Yet, it is conceivable
that α5β1 helps triple-negative breast cancer cells survive in
the bone marrow until environmental conditions are suffi-
ciently permissive for tumor growth, at which time integrin
switching from α5β1 to αvβ3 triggers pro-invasive signals.
This hypothesis warrants further investigation.
Having shown that there is an explicit role for ITGA5 in
mediating early breast cancer cell colonization in the bone
marrow, we then investigated whether ITGA5 also plays a
role in the development of metastatic skeletal lesions. In
bone metastasis, there is a vicious cycle where tumor cells
stimulate osteoclast-mediated bone resorption and, in turn,
bone-derived growth factors released from resorbed bone
stimulate skeletal tumor burden [2]. We showed that the
silencing or pharmacological inhibition of ITGA5 markedly
reduced tumor outgrowth in experimental models of bone
metastasis or tumorigenesis. This inhibition of tumor growth
(and subsequent overall decrease in the secretion of tumor-
derived pro-osteoclastic factors) led to the reduction in
osteoclast-mediated bone destruction as would be predicted
by the vicious cycle theory. However, there is some evi-
dence in the literature showing that human osteoblasts and
osteoclasts do express ITGA5 [35, 44]. It is possible that
M200 could act upon human osteoblast differentiation. Here,
we found that a clinically relevant concentration of M200
antibody was nearly as effective as the anti-RANKL anti-
body denosumab to inhibit human osteoclast differentiation
Fig. 6 Pharmacological
inhibition of ITGA5 with
M200 treatment reduces
growth of subcutaneous tumor
xenografts in vivo.
A Schematic representation of
the treatment protocol. MDA-
B02 cells were inoculated
subcutaneously to Balb/c nude
mice. Animals (five mice per
group) received a treatment with
a control IgG or M200 (15 mg/
kg) every other day, starting
1 day before tumor cell
inoculation. Tumor growth in
animals was monitored over
time by bioluminescence
imaging and using a vernier
caliper. At day 35 after tumor
cell inoculation animals were
culled and tumors weighted.
B Left panel: whole-body
bioluminescence imaging of
three representative mice per
group at day 35. Right panel:
tumor burden curves of tumor-
bearing animals treated with the
control IgG or M200, as judged
by bioluminescence imaging
(photons/second). C Tumor
growth curves of tumor-bearing
animals treated with the control
IgG or M200, as judged by
vernier caliper measurement
(mm3). D Bar graph represents
the average weight of tumors for
each group. Data are presented
as mean ± SEM. *p < 0.05;
**p < 0.01; ***p < 0.005.
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for. . .
and activity in vitro. Thus, in addition to its antitumor effect,
we anticipate antibody M200 may also be effective at
inhibiting bone resorption.
Clinical trials have repeatedly failed to demonstrate ther-
apeutic benefits of integrin inhibitors in cancer patients [34].
Volociximab has shown preliminary evidence of efficacy in
early phase I/II trials but failed in larger phase III trials
[18, 20, 21]. However, none of these clinical trials using
patients with advanced cancer and metastasis have specifi-
cally addressed the efficacy of volociximab on bone metas-
tasis. A focus for further work would be to establish if
ITGA5-positive breast cancer patients with bone metastases
are likely to benefit from volociximab in combination with
denosumab, which is the best standard of care for prevention
of the skeletal morbidity associated with bone metastases in
patients with advanced malignancies [2].
Fig. 7 Pharmacological inhibition of ITGA5 with M200 antibody
inhibits human osteoclast differentiation and activity in vitro.
A ITGA5 and cathepsin K mRNA expression levels (relative to GSUb
housekeeping gene) at different stages of human osteoclast differ-
entiation. B Western blot analysis of ITGA5 at different stages of
human osteoclast differentiation. C Fluorescence-based staining of
ITGA5 and F-actin ring (white arrowheads) at different stages of
human osteoclast differentiation, using phycoerythrin-conjugated anti-
ITGA5 antibody and FITC-labeled phalloidin, respectively. Scale bar:
100 μm. D In vitro osteoclast differentiation of human peripheral blood
mononuclear cells treated with M-CSF and RANKL, alone (Ctrl) or in
combination with anti-RANKL antibody denosumab (250 μg/ml) or
anti-ITGA5 antibody M200 (250 μg/ml). Mature osteoclasts were
quantified as multinucleated (more than three nuclei), TRAP-positive
cells. Representative images are shown for each group. *,**p < 0.05
and 0.001, respectively. E Resorption of an inorganic three-
dimensional crystalline material by human osteoclasts treated with a
control IgG or M200 (250 μg/ml). Representative images are shown
for each group. *p < 0.05. F Effect of control IgG and M200 on via-
bility of human osteoclasts, as measured by MTT assay.
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Material and methods
Patients
ITGA5 mRNA expression was quantified by RT-qPCR in
primary breast carcinomas obtained from the Curie Insti-
tute/René Huguenin Hospital (Saint-Cloud, France) [28].
ITGA5 protein immunohistochemistry was performed
using primary tumors from breast cancer patients for
whom the presence or absence of DTCs in bone marrow
aspirates was known (University Medical Center Ham-
burg-Eppendorf, Germany) [29, 30, 45, 46].
Analysis of human breast tumor microarray data
sets
Analysis were conducted using public breast cancer
microarray data sets GSE2034, GSE12276, GSE2603, and
NKI295, consisting of 855 patients with clinical outcomes
[47], and data sets GSE11078 and GSE14020 for 80 distant
breast cancer metastases [48, 49].
Real-time qPCR
PCR experiments were conducted as previously described
[50]. All primers are shown in Table S3.
Tissue microarray and immunohistochemistry
Immunodetection of ITGA5 in breast tumor tissue
microarrays was performed following a previously
described method [4].
Cell lines and cell transduction
Human breast cancer cell lines T47D, MCF-7, Hs587T,
SKBR3, BT-474, and MDA-MB-231 were obtained
from the American Type Culture Collection (Manassas,
VA) and authenticated using short tandem repeat ana-
lysis. The human MDA-B02 breast cancer cell line
(MDA-B02) is a subpopulation of the MDA-MB-231
cell line (MDA-MB-231) that was selected for its high
and selective efficiency to metastasize to bone in mice
[33, 51].
Stable silencing of ITGA5 was achieved in
luciferase2-expressing MDA-MB-231 and MDA-BO2
cells (MDA-231-shITGA5 and MDA-BO2-shITGA5,
respectively) by transduction with lentiviral plasmids
containing hairpin shRNAs targeting ITGA5. ITGA5 was
overexpressed in luciferase2-expressing MCF-7 cells
(MCF-7luc2 ITGA5) using the amphotropic retroviral
packaging system (Clontech).
Cell-based assays
Tumor cell functions were investigated using cell adhesion
and migration assays, and cell-cycle analysis, as previously
described [40, 52, 53]. The effect of antibody M200 on
differentiation of mature osteoclasts or osteoblasts was
studied using previously described methods [36, 40, 54].
Animal studies
All procedures involving animals, including housing and
care, method of euthanasia, and experimental protocols
were conducted in accordance with a code of practice
established by the local ethical committee (Comité
d’Expérimentation Animale de l’Université Claude Ber-
nard Lyon 1, CEEA-55) under project licence MESR
Number: APAFIS#4798-2016040510106615. Four-week-
old female BALB/c nude mice were purchased from
Janvier Laboratories (Saint-Berthevin). For bone metas-
tasis experiments, immunodeficient BALB/c female nude
mice were randomly assigned to receive intraperitoneal
injection of M200 antibody or control IgG (15 mg/kg)
1 day before tumor cell injection. MDA-BO2 cells were
then inoculated into the tail artery (5.105/100 μL of PBS)
of anesthetized mice at day 0. Alternatively, MDA-BO2
shCtrl or MDA-BO2 shITGA5 cells (5.105/100 μL of
PBS) were inoculated into the tail artery. Hormone-
responsive MCF-7luc2 ITGA5 and MCF-7luc2 control
cells (4 × 105 cells/100 μL of PBS) were injected intra-
arterially to female BALB/c nude mice 2 days after sub-
cutaneous implantation of 17β-estradiol pellet in animals.
Measurements of the extent of osteolytic lesions and
skeletal tumor burden were performed by radiography/
microcomputed tomography and bioluminescence ima-
ging, respectively, as previously described [40, 51–53].
On day 28 after tumor cell inoculation, anesthetized mice
were sacrificed by cervical dislocation, and hind limbs
were collected and embedded in paraffin for further ana-
lyses by histomorphometry, histology, and immunohis-
tochemistry. Ex vivo bone marrow micrometastasis and
tumorigenesis experiments were conducted as previously
described [40, 51–53].
Statistical analysis
All statistical analyses were performed using PASW Sta-
tistics (version 21.0; SPSS Inc., Chicago) or GraphPad
Prism (version 5, San Diego) [55]. All in vitro experimental
procedures consisted of at least three independent biological
repeats, and appropriate negative and positive controls.
Comparisons were performed using two-sided unpaired
Student’s t test or ANOVA test followed by Tukey’s test for
Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for. . .
in vitro experiments and by Mann–Whitney U test for
in vivo experiments with significance at <0.05 being used to
determine significant differences. Cox proportional regres-
sion model was used to estimate hazard ratios and 95% CIs
for distant relapse to bone in relation to the ITGA5
expression as a continuous variable, with adjustment for
classic prognostic factors: age, tumor size, node involve-
ment, estrogen receptor and progesterone receptor status,
and Her2 status. Survival analyses were visualized using
Kaplan–Meier plots and differences in survival across the
strata were calculated using a log-rank p-test. In total, data
were obtained from 855 patients with, as the first site of
relapse, bone (n= 238), brain (n= 49), lung (n= 101), or
liver metastasis (n= 107). For analyses of bone relapse free
survival, non-bone events, including liver, lung, and brain
relapses were censored.
The power calculation for ex vivo experiments is based
on our previous work [40, 52, 53], showing that bone
marrow micrometastases occur in 80% of animals. Simi-
larly, for bone metastasis experiments, 80% of animals have
skeletal lesions 4 weeks after intra-arterial tumor cell
inoculation [17, 40, 51–53]. Assuming a power of 80% and
a level of significance of 5%, we estimated that we will be
able to measure a difference of 60% or greater with ten
animals per group, using a Mann–Whitney test. With regard
to tumor xenograft experiments, the tumor take in this
animal model is 90–100%. From our previous work
[17, 40, 51–53], assuming a power of 80% and a level of
significance of 5%, we estimated that we will be able to
measure a difference of 60% or greater with five animals per
group, using a Mann–Whitney test. Only the animals that
were alive at the end of the protocols were included in the
statistical analyses.
In order to avoid bias for in vivo experiments, staff
injecting transduced tumor cells into animals were different
from those assessing the effects of transduction. Mice and
subsequent tissue samples were labeled such that staff
assessing the effects of transduction and analyzing the
results were unaware which group received mock-
transduced tumor cells or tumor cells in which ITGA5 was
silenced or overexpressed until analyses were complete.
Additional methods
A more detailed description of methods outlined above and
additional methods used in this study are provided in
Supplementary Methods section.
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